Audentes Therapeutics (BOLD) Stock Rating Reaffirmed by William Blair

Audentes Therapeutics (NASDAQ:BOLD)‘s stock had its “buy” rating reissued by stock analysts at William Blair in a research note issued on Thursday. William Blair also issued estimates for Audentes Therapeutics’ Q2 2018 earnings at ($0.79) EPS, Q3 2018 earnings at ($0.83) EPS, Q4 2018 earnings at ($0.86) EPS, FY2018 earnings at ($3.22) EPS, Q1 2019 earnings at ($0.87) EPS, Q2 2019 earnings at ($0.91) EPS, Q3 2019 earnings at ($0.93) EPS, Q4 2019 earnings at ($0.83) EPS and FY2019 earnings at ($3.54) EPS.

The analysts wrote, “We view the update as a positive and initial safety concerns as largely overblown, particularly when compared with the data from the INCEPTUS run-in study and noting that the majority were in a single patient who had previously experienced several pneumonia episodes, a tachycardic event in the run-in trial, and was on 24 hours of invasive ventilation at baseline.””

BOLD has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a research note on Thursday, March 8th. HC Wainwright set a $37.00 target price on shares of Audentes Therapeutics and gave the company a “buy” rating in a research note on Friday, March 9th. Wedbush restated an “outperform” rating and set a $56.00 target price on shares of Audentes Therapeutics in a research note on Friday, March 9th. Cowen restated a “buy” rating on shares of Audentes Therapeutics in a research note on Friday, March 9th. Finally, Raymond James reiterated a “hold” rating on shares of Audentes Therapeutics in a research note on Friday, May 11th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $35.89.

Audentes Therapeutics opened at $38.24 on Thursday, according to MarketBeat Ratings. Audentes Therapeutics has a fifty-two week low of $13.90 and a fifty-two week high of $42.61.

Audentes Therapeutics (NASDAQ:BOLD) last released its earnings results on Wednesday, May 9th. The biotechnology company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.07. research analysts forecast that Audentes Therapeutics will post -3.31 earnings per share for the current year.

In other Audentes Therapeutics news, VP Suyash Prasad sold 1,900 shares of the business’s stock in a transaction on Monday, March 26th. The shares were sold at an average price of $30.00, for a total value of $57,000.00. Following the sale, the vice president now owns 1,900 shares in the company, valued at approximately $57,000. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Louis G. Lange sold 48,000 shares of the business’s stock in a transaction on Monday, March 26th. The stock was sold at an average price of $28.89, for a total transaction of $1,386,720.00. Following the completion of the sale, the director now owns 414,231 shares in the company, valued at approximately $11,967,133.59. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,138,107 shares of company stock worth $39,502,022. Corporate insiders own 47.30% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. BlackRock Inc. increased its holdings in shares of Audentes Therapeutics by 44.3% in the 1st quarter. BlackRock Inc. now owns 1,960,404 shares of the biotechnology company’s stock worth $58,910,000 after buying an additional 601,906 shares during the last quarter. Sofinnova Ventures Inc bought a new stake in shares of Audentes Therapeutics in the 1st quarter worth about $41,478,000. Redmile Group LLC increased its holdings in shares of Audentes Therapeutics by 40.8% in the 1st quarter. Redmile Group LLC now owns 1,308,526 shares of the biotechnology company’s stock worth $39,321,000 after buying an additional 379,200 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of Audentes Therapeutics by 1.2% in the 4th quarter. Jennison Associates LLC now owns 853,822 shares of the biotechnology company’s stock worth $26,682,000 after buying an additional 9,762 shares during the last quarter. Finally, Rock Springs Capital Management LP increased its holdings in shares of Audentes Therapeutics by 7.6% in the 1st quarter. Rock Springs Capital Management LP now owns 565,000 shares of the biotechnology company’s stock worth $16,978,000 after buying an additional 40,000 shares during the last quarter. Institutional investors and hedge funds own 69.43% of the company’s stock.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply